SCHEMBL21269477

SCHEMBL21269477

CC(C)C(Cc1ccccc1)(C(=O)O)C(=O)O.[NaH]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 1/20 0.50
TRPA1 O75762 2/20 0.46
CYP1A2 P05177 3/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SLC6A2 P23975 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
KCNH2 Q12809 2/20 0.40
OPRM1 P35372 2/20 0.40
OPRD1 P41143 2/20 0.40
MRGPRX2 Q96LB1 1/20 0.40
CHRM3 P20309 1/20 0.40
HRH2 P25021 1/20 0.40
HTR2A P28223 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28314702 0.98 SMN1; SMN2 (0.48) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL28314546 0.98 SMN1; SMN2 (0.48) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL28314443 0.96 SMN1; SMN2 (0.50) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL28315549 0.96 SMN1; SMN2 (0.50) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL21269478 0.96 SMN1; SMN2 (0.50) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL28875971 0.96 SMN1; SMN2 (0.50) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL21269521 0.96 SMN1; SMN2 (0.50) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL28314666 0.94 SMN1; SMN2 (0.48) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL9358974 0.84 SMN1; SMN2 (0.43) SMN1; SMN2HIF1ATRPA1CYP1A2CYP2D6
SCHEMBL8999081 0.83 HPGD (0.41) SMN1; SMN2CYP1A2CYP2D6PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110172019-A The metal salt of malonic acid as the nucleating additive for crystalline thermoplastic 印度石油有限公司 2019-08-27 CN claimed
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION LIMITED (IN) 2019-08-22 US claimed
EP-3527616-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION Ltd. (IN) 2019-08-21 EP claimed
EP-3527616-B1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORP LTD (IN) 2024-02-07 EP disclosed
CN-110172019-B Metal salts of malonic acid as nucleating additives for crystalline thermoplastics 印度石油有限公司 2022-03-04 CN disclosed
US-11180630-B2 Metal salts of malonic acid as nucleating additives for crystalline thermoplastics INDIAN OIL CORPORATION LIMITED (IN) 2021-11-23 US disclosed
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION LIMITED (IN) 2019-08-22 US disclosed
EP-3527616-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION Ltd. (IN) 2019-08-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS NUMA1, MNS1, ME1 SMN1; SMN2 901/4885HIF1A 2238/4885TRPA1 3397/4885
US-11180630-B2 Metal salts of malonic acid as nucleating additives for crystalline thermoplastics NUMA1, MNS1, ME1 SMN1; SMN2 901/4885HIF1A 2238/4885TRPA1 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.